Correspondence 0001213900-23-022372 from Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936) (CYTOF)
Altamira Therapeutics Ltd. (CYTO) (CIK 0001601936)
Date: March 23, 2023 · CIK: 0001601936 · Accession: 0001213900-23-022372
AI Filing Summary & Sentiment
File numbers found in text: 333-269823
Letter
ThinkEquity LLC
17 State Street, 41st Floor
New York, NY 10004
March 23, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F St., NE
Washington, D.C. 20549
Re: Altamira Therapeutics Ltd.
Withdrawal of Request for Acceleration
Registration Statement on Form F-1 (File No. 333-269823)
Ladies and Gentlemen:
On March 17, 2023, ThinkEquity LLC, as representative of the underwriters, requested acceleration of the effective date of the above-referenced Registration Statement so that it would become effective at 5:00PM on Tuesday, March 21, 2023 or as soon thereafter as practicable. We hereby withdraw such request.
Very truly yours,
ThinkEquity LLC
Show Raw Text
CORRESP
1
filename1.htm
ThinkEquity LLC
17 State Street, 41st Floor
New York, NY 10004
March
23, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F St., NE
Washington, D.C. 20549
Re:
Altamira Therapeutics Ltd.
Withdrawal of Request for Acceleration
Registration Statement on Form F-1 (File No. 333-269823)
Ladies and Gentlemen:
On
March 17, 2023, ThinkEquity LLC, as representative of the underwriters, requested acceleration of the effective date of the above-referenced
Registration Statement so that it would become effective at 5:00PM on Tuesday, March 21, 2023 or as soon thereafter as practicable. We
hereby withdraw such request.
Very truly yours,
ThinkEquity LLC
By:
/s/ Eric Lord
Name:
Eric Lord
Title:
Head of Investment Banking